Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy

Non-small Cell Lung Cancer Stage III Clinical Trial

— MERIT-lung  

Official title:

Phase II Clinical Trial of AMG510 (Sotorasib) in Stage III Unresectable NSCLC KRAS p.G12C Patients and Medically Ineligible for Concurrent Chemo-radiotherapy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05398094
• Other study ID #: GECP 20/10_MERIT-lung
• Secondary ID: 2021-004576-34
• Status: Recruiting
• Phase: Phase 2
• Start date: March 21, 2022
• Est. completion date: December 31, 2028

Study information

• Verified date: August 2023
• Source: Fundación GECP
• Contact: Eva Pereira
• Phone: 934302006
• Email: gecp[@]gecp.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Open-label, non-randomised, exploratory, phase II, multi-centre clinical trial. 43 unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer patients will be enrolled in this trial to evaluate the efficacy of induction treatment of AMG510 (Sotorasib) plus AMG510 (Sotorasib) treatment post-induction as measured by Progression Free Survival at 12 months.

Description:

This is an open-label, non-randomized, exploratory, phase II multi-centre clinical trial.The total sample size is 43 patients. The population to be included are unresectable stage III (IIIA-N2, IIIB, IIIC) KRAS p.G12C non-small cell lung cancer patients.

Patients randomised will receive AMG510 (Sotorasib) 960mg once daily for 2 cycles (Q4W) in the induction phase and AMG510 (Sotorasib) 960 mg once daily (Q4W) in the treatment post-induction phase. Treatment post-induction phase only for patients with SD, PR or CR after induction treatment. This treatment will be administered until progression disease (PD), unacceptable toxicity, patient or physician's decision to discontinue or death.

The primary objective is to assess the efficacy of induction treatment of AMG510 (Sotorasib) plus AMG510 (Sotorasib) treatment post-induction as measured by Progression Free Survival at 12 (PFS12) months according to Response Evaluation Criteria in Solid Tumors (RECIST) version PFS are defined as the time from inclusion until objective tumor progression or death.

Patient accrual is expected to be completed within 5 years and a half, treatment is planned to extend for 1.5 years and the patients will be followed up for 2 years. The study will end once survival follow-up has concluded.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 43
• Est. completion date: December 31, 2028
• Est. primary completion date: December 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 1. Male or female, aged = 80 years old

• 2. ECOG performance status of 0-1

• 3. Histologically or cytologically confirmed, unresectable Stage III (IIIA-N2, IIIB and IIIC) NSCLC according to 8th version of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology.

• 4. Patients who have documentation of KRAS p.G12C prior to enrollment. This determination can be done either by solid or liquid biopsy.

• 5. No prior treatment for unresectable Stage III (IIIA-N2, IIIB and IIIC) NSCLC.

• 6. Having a life expectancy = 12 weeks

• 7. Patients must be ineligible for concurrent chemo-radiotherapy because of:

1. Tumor size = 5 cm and lymph node N2 involvement

2. The target lesion has to be bulky disease and/or more than 35% of the total volume of the two lungs should receive more than 20 Gy (V20) or inadequate pulmonary function

3. Interstitial Lung diseases

4. Prior treatment with thoracic radiotherapy for any reason

5. Or under decision of a tumor committee as inappropriate due to local characteristics to perform treatment upfront

• 8. PET-CT at baseline is mandatory to confirm the absence of distant disease and to confirm unresectable disease

• 9. PET-CT positive mediastinic adenopathies must be histologically confirmed. Mediastinic involvement could be considered without histological test when no margin can be distinguished in the lymph node mass.

• 10. Brain CT or MRI is mandatory

• 11. Patients with at least 1 measurable lesion, as defined by RECIST v1.1.

• 12. Adequate hematologic and organ function.

• 13. All patients are notified of the investigational nature of this study and signed a written informed consent in accordance with institutional and national guidelines, including the Declaration of Helsinki prior to any trial-related intervention.

• 14. Willingness and ability to comply with scheduled visits and study procedures

• 15. For female patients of childbearing potential, a negative pregnancy test must have been documented prior to enrollment (within 14 days prior to enrollment).

• 16. For female patients of childbearing potential, agreement (by patient and/or partner) to usea highly effective form(s) of contraception that results in a low failure rate (< 1% per year)when used consistently and correctly, and to continue its use for 7 days after the last dose of AMG510 (Sotorasib). No hormonal methods and preferably barrier method always containing a spermicide, intrauterine device (IUD): intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner (on the understanding that this is the only one partner during the whole study duration), and sexual abstinence.

• 17. For male patients with female partners of childbearing potential, agreement (by patient and/or partner) to use a highly effective form(s) of contraception that results in a low failure rate [< 1% per year] when used consistently and correctly, and to continue its use for 7 days after the last dose of AMG510 (Sotorasib).

• 18. Women who are not postmenopausal (= 12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to enrollment.

• 19. QTc interval must be = 470 msec in females and = 450 msec in males, based on the average obtained from three ECG.

Exclusion Criteria:

• 1. Patients with a known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene, ALK translocations or ROS1 mutations

• 2. Weight loss >10% within the previous 3 months

• 3. Patients with uncontrolled neuropathy (sensory) grade 2 or greater regardless of cause according to CTCAE v5.0

• 4. Major surgery within 28 days of study day 1

• 5. Significant gastrointestinal disorder that results in significant malabsorption, requirement for intravenous alimentation, or inability to take oral medication

• 6. Significant cardiovascular disease, such as New York Heart Association cardiac disease (ClassII or greater), myocardial infarction within 6 months prior to study day 1, unstable arrhythmias or unstable angina

• 7. Ongoing cardiac dysrhythmias of CTCAE grade =2, uncontrolled atrial fibrillation of any grade or QTcF interval > 470ms

• 8. Severe infections within 4 weeks prior to randomization including, but not limited to hospitalization for complications of infection, bacteremia or severe pneumonia

• 9. Therapeutic oral or intravenous antibiotics within 2 weeks prior to randomization

• 10. Patients with any concomitant and uncontrolled medical disorder

• 11. Patients with vena cava syndrome

• 12. Malignant pleural or pericardial effusion: both will be considered as suggestive of metastaticdisease. Also, are excluded those with negative cytology but being exudates. Patients with non-visible by thoracic X-ray pleural effusion or too small to be safely punctured could be included.

• 13. Prior treatment with anti-neoplasic drugs

• 14. Malignancies other than NSCLC within 3 years prior to enrollment

• 15. Women who are pregnant, lactating, or intending to become pregnant during the study.

• 16. Positive test for HIV. All patients will be tested for HIV prior to inclusion into the study; patients who test positive for HIV will be excluded from the clinical study.

• 17. Patients with active hepatitis B or hepatitis C.

• 18. Active tuberculosis.

• 19. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.

• 20. Patients with illnesses or conditions that interfere with their capacity to understand follow and/or comply with study procedures.

• 21. Known or suspected hypersensitivity to drugs with similar chemical structures to the study drug

• 22. Evidence of any other disorder or significant laboratory finding that makes the patient undesirable to participate in the study

• 23. Use of strong inducers of CYP3A4 within 14 days of half-lives (whichever is longer) prior to study day 1

• 24. Use of proton pump inhibitors within 14 days to study day

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer Stage III

Intervention

Drug:
• Sotorasib
AMG510 (Sotorasib) is small molecule that specifically and irreversibly inhibits the KRAS-G12C mutant protein. AMG510 (Sotorasib) finished product is presented as tablets containing 120mg and will be packaged in bottles of 120 tablets.

Locations

Country	Name	City	State
Spain	Hospitalario Universitario A Coruña	A Coruña	La Coruña
Spain	Hospital General Universitario de Alicante	Alicante
Spain	ICO Badalona, Hospital Germans Trias i Pujol	Badalona	Barcelona
Spain	Hospital Parc Taulí	Barcelona
Spain	Hospital Universitari Quiron Dexeus	Barcelona
Spain	Hospital Universitari Vall d' Hebron	Barcelona
Spain	Hospital De Basurto	Bilbao
Spain	ICO Girona, Hospital Josep Trueta	Girona
Spain	Hospital Clínico San Cecilio De Granada	Granada
Spain	Complejo Hospitalario De Jaén	Jaén
Spain	Hospital Universitario Severo Ochoa	Leganés	Madrid
Spain	Hospital Universitario Lucus Augusti	Lugo
Spain	Hospital Clínico San Carlos	Madrid
Spain	Hospital Universitario Fundación Jiménez Díaz	Madrid
Spain	Hospital Universitario Puerta de Hierro	Majadahonda	Madrid
Spain	Hospital de Son Espases	Palma De Mallorca	Mallorca
Spain	Hospital Universitari Son Llatzer	Palma De Mallorca
Spain	Hospital Universitario Virgen Del Rocio	Sevilla
Spain	Hospital General Universitario De Valencia	Valencia
Spain	Hospital Universitario La Fe	Valencia

Sponsors (1)

Lead Sponsor	Collaborator
Fundación GECP

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of the treatment in terms of the Progression Free Survival (PFS)	PFS defined as the length of time from the date of end of post-induction treatment to the date of the first documented progression of disease	From the date of the end of treatment until 12 months
Primary	Efficacy of the treatment in terms of the Progression Free Survival (PFS)	PFS defined as the length of time from the date of end of post-induction treatment to the date of the first documented progression of disease	From the date of the end of treatment until 24 months
Secondary	Overall response rate (ORR) of AMG510 (Sotorasib)	Overall response will be assessed per RECIST v1.1 criterion. ORR is defined as the proportion of patients who have a partial or complete response to therapy; it does not include stable disease and is a direct measure of drug tumoricidal activity.	From the date of the end of treatment until 12 months and 24 months
Secondary	Overall Survival (OS) rate of treatment with AMG510 (Sotorasib)	OS defined as the length of time from either the date of diagnosis or the start of the treatment that patients diagnosed with the disease are still alive.	From the date of the start of treatment until 12 and 24 months
Secondary	Detect and collect the sites of first failure	Sites of the first failure defined as the first site of the body of documented relapse or progression of the lung cancer disease after a period of improvement.	From the date of the start of treatment until the date of last follow up, assessed up to 24 months
Secondary	Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)	Occurrence and severity of adverse events, with severity determined by NCI CTCAE v5.0 criteria.	From the subject written informed consent signature to 30 days from last dose of treatment.

External Links

•   Web page of the sponsor where users can find more information about Fundación GECP studies